|
1
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
2
|
Yang Y, Song X, Zhu J and Zhou X: A rare
case of adenocarcinoma of the lung harboring EGFR, BRAF, and ALK
activating mutations. Chest 146 (4_MeetingAbstracts).
640A:2014.
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Li Y, Yang T, Wei S, Wang J, Wang M,
Wang Y, Zhou Q, Liu H and Chen J: Clinical significance of EML4-ALK
fusion gene and association with EGFR and KRAS gene mutations in
208 Chinese patients with non-small cell lung cancer. PLoS One.
8:e520932013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JK, Kim TM, Koh Y, Lee SH, Kim DW,
Jeon YK, Chung DH, Yang SC, Kim YT, Kim YW, et al: Differential
sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR
mutation and ALK translocation. Lung Cancer. 77:460–463. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sasaki T, Koivunen J, Ogino A, Yanagita M,
Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J and Okuda K: A
novel ALK secondary mutation and EGFR signaling cause resistance to
ALK kinase inhibitors. Cancer Res. 71:6051–6060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu JY, Wu SG, Yang CH, Chang YL, Chang YC,
Hsu YC, Shih JY and Yang PC: Comparison of gefitinib and erlotinib
in advanced NSCLC and the effect of EGFR mutations. Lung Cancer.
72:205–212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H and Hirashima T:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 triaL. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Zhang J, Hu Q, Li X and Zhou C: A
case of lung adenocarcinoma harboring exon 19 EGFR deletion and
EML4-ALK fusion gene. Lung Cancer. 81:308–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyanaga A, Shimizu K, Noro R, Seike M,
Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A,
Kawamoto M, et al: Activity of EGFR-tyrosine kinase and ALK
inhibitors for EML4-ALK-rearranged non-small-cell lung cancer
harbored coexisting EGFR mutation. BMC Cancer. 13:2622013.
View Article : Google Scholar : PubMed/NCBI
|
